Alvotech is a biopharmaceutical company specializing in the development and manufacturing of biosimilar medicines. Headquartered in Reykjavík, Iceland, the company focuses on creating high-quality, cost-effective alternatives to branded biologic therapies. Since its founding in 2013, Alvotech has built an integrated platform that spans research and development, clinical trials, regulatory submissions and commercial manufacturing.
Alvotech’s pipeline includes multiple biosimilar candidates addressing key therapeutic areas such as immunology, oncology and ophthalmology. The company’s lead product, AVT02, is a biosimilar to adalimumab (marketed as Humira) and has been submitted to major regulatory authorities including the U.S. Food and Drug Administration and the European Medicines Agency. Additional candidates in the pipeline target well-established biologics like bevacizumab and ranibizumab, showcasing Alvotech’s commitment to expanding patient access to proven treatments.
To commercialize its biosimilars globally, Alvotech has entered into strategic partnerships with established pharmaceutical firms that can provide marketing, distribution and regulatory expertise in key regions. These alliances support the company’s efforts to bring more affordable biologic therapies to markets across North America, Europe and select emerging economies. Alvotech’s manufacturing facility in Reykjanes, Iceland, is designed to meet stringent international quality standards, ensuring a reliable supply of its products.
Under the leadership of Chief Executive Officer Robert Wessman, Alvotech continues to invest in its R&D capabilities and expand its pipeline. The company’s experienced management team includes professionals with extensive backgrounds in biologics development, regulatory affairs and commercial strategy. As Alvotech advances its biosimilar candidates through clinical and regulatory milestones, it remains focused on delivering accessible, high-quality therapies to patients worldwide.
AI Generated. May Contain Errors.
